Baum, Hedlund, Aristei & Goldman  has extensive experience in litigating personal injury, wrongful death and consumer class action cases against major drug companies and has been litigating a number of different types of cases against GlaxoSmithKline (GSK), the maker of Avandia®, for many years.  

Over the course of this litigation, Baum Hedlund has collected hundreds of thousands of pages of internal GSK documents and conducted dozens of depositions of GSK executives, employees, physicians, researchers and academics. As a result, Baum Hedlund knows how GSK operates, knows its tactics, the players, and how to get the evidence needed to effectively litigate cases against GSK.*

Baum Hedlund has been on the prevailing side of some of the nation's most highly-publicized cases. Many of their attorneys have delivered Continuing Legal Education accredited lectures and written articles published in legal journals on the many complex issues involved in pharmaceutical litigation.

Legal Actions Against GSK

In 2001, Baum Hedlund was appointed lead counsel in charge of the Plaintiffs’ Steering Committee for the Paxil Products Liability Litigation (Multidistrict Litigation MDL-1574) in which Baum Hedlund represented over 3,000 people across the United States in personal injury cases against GSK.

Baum Hedlund has also been litigating Paxil suicide and suicide attempt cases for the past several years.

Since 2004, Baum Hedlund has been litigating a Private Attorney General consumer fraud class action lawsuit against GSK on behalf of residents in the states of California, Florida, Massachusetts, Nevada, New Jersey, Pennsylvania, Texas and Washington related to GSK’s false promotion of Paxil as an effective medication for children and adolescents. A settlement was reached in April 2007 wherein GSK agreed to reimburse parents for the money they paid for their children’s Paxil prescriptions.

Beginning in 2006, Baum Hedlund filed a number of antidepressant birth defect cases including heart defects and PPHN (Persistent Pulmonary Hypertension of the Newborn).

Drug Safety Advocates

Baum Hedlund has been a strong advocate for publicly exposing the serious risks of certain drugs and pushing for increased warnings.

A Baum Hedlund attorney testified four times before the government, regarding the need for proper warnings on antidepressants. We testified about the dangers of SSRI (Selective Serotonin Reuptake Inhibitor) antidepressants before the California State Senate and the Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee and met with members of the U.S. House and Senate regarding the risk of antidepressant induced suicidality.

Our law firm assisted Congressional Investigators from two separate Committee investigations. Two Congressional hearings were later held at which pharmaceutical executives and FDA officials were interrogated about their failure to protect the public health related to antidepressants and their association with suicidality.

The FDA now requires a black box warning on all antidepressant labels alerting physicians and patients to the increased risk of suicidality, which warnings went into effect in January 2005.

Baum Hedlund has also represented more than 100 families of hemophiliacs infected by HIV contaminated blood-derived products (used by hemophiliacs for blood coagulation). It was considered one of the worst drug industry related medical disasters in history. As with all of its drug litigation, Baum Hedlund dug deep into drug company coffers to find the evidence of what went wrong. That information was not only used at trial, but also provided to authorities in various countries.

After reading a quote in the New York Times by senior partner, Michael Baum, Taiwan’s Ministry of Health invited him to their country for an urgent meeting. Michael Baum traveled to Taiwan and shared the firm’s collection of smoking gun documents with the Ministry, showing them that the U.S. manufacturers of hemophilia blood-derived products were knowingly urging doctors to prescribe HIV contaminated medication to their hemophilia community. Representatives of hemophilia communities in Ireland and Hong Kong have also consulted with Michael concerning his knowledge of the U.S. manufacturers blood-derived product contamination and dumping activities.

Another Baum Hedlund partner, senior trial attorney, Ron Goldman, was involved in ground-breaking drug litigation in the 1960s. Ron was actively involved in exposing severe side effects, including birth defects, associated with the cholesterol-lowering drug MER/29 (triparanol), manufactured by Richardson-Merrell (later known as Marion Merrell Dow). The company was ultimately indicted for supplying the FDA with falsified information about the drug. Ron Goldman is a veteran trial lawyer; board certified as a civil trial lawyer, certified by the National Board of Trial Advocacy.

Cynthia Garber has many years of experience handling wrongful death and catastrophic personal injury cases stemming from defective pharmaceutical medications and medical devices. Her extensive medical background as a registered nurse and her scientific expertise has placed her on numerous committees, including science committees, in mass tort litigation concerning pharmaceutical product liability. Cynthia’s medical knowledge, coupled with her trial experience and public speaking background, has proven invaluable to her practice.

MDL No. 1871, In re Avandia Marketing, Sales Practices & Products Liability, was formed in October 2007 by the Judicial Panel on Multidistrict Litigation in the Eastern District of Pennsylvania where GSK’s U.S. headquarters is located, where many witnesses reside, and where many relevant documents are located.

The MDL will address common fact questions regarding GSK's manufacture and marketing of Avandia, Avandamet and Avandaryl.


*Past results do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter.